As of Friday close, Amicus Therapeutics Inc.’s (NASDAQ:FOLD) stock was up $0.05, moving up 0.41 percent to $12.26. The average number of shares traded per day over the past five days has been 1,735,620 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.83 fall in that time frame. In the last twenty days, the average volume was 1,955,715, while in the previous 50 days, it was 2,315,934.
Since last month, FOLD stock retreated -3.16%. Shares of the company fell to $11.91 on 09/21/23, the lowest level in the past month. A 52-week high of $14.10 was reached on 08/09/23 after having rallying from a 52-week low of $9.10. Since the beginning of this year, FOLD’s stock price has risen by 0.41% or $0.05, and marked a new high 8 times. However, the stock has declined by -13.05% since its 52-week high.
FOLD stock investors should be aware that Amicus Therapeutics Inc. (FOLD) stock had its last reported insider trading activity 8 days ago on Sep 15. Crowley John F, the Executive Chairman of the company, disposed of 6,044 shares for $13.06 on Sep 15. It resulted in a $78,964 divestment by the insider. Campbell Bradley L sold 18,093 shares at an average price of $12.97 on Sep 01. The insider now owns 792,161 shares following the transaction. On Sep 01, Executive Chairman Crowley John F sold 6,044 shares at $12.98 apiece. The transaction was valued at $78,447.
Valuation Metrics
The stock’s beta is 0.86. Besides these, the trailing price-to-sales (P/S) ratio of 10.06, the price-to-book (PB) ratio of 32.26.
Financial Health
In the three months ended June 29, Amicus Therapeutics Inc.’s quick ratio stood at 2.40, while its current ratio was 2.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.53, and the total debt-to-equity ratio was 3.53. On the profitability front, the trailing twelve-month gross margin is 88.90% percent. In the year ended June 29, EBITDA margin amounted to -60.47%, whereas operating margins totaled -37.80%. Based on annual data, FOLD earned $290.63 million in gross profit and brought in $329.23 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -40.10%. Return on equity (ROE) for the past 12 months was -157.80%.
In Amicus Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $393.35 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. FOLD’s revenue rose 14.47% to $86.27 million during the quarter, while net income inched up to $94.39 million. While analysts expected Amicus Therapeutics Inc. to report -$0.12 quarterly earnings, the actual figure was -$0.15 per share, beating the consensus estimate by -25.00%. During the quarter, the company generated -$15.96 million in EBITDA. The liabilities of Amicus Therapeutics Inc. were 618.51 million at the end of its most recent quarter ended June 29, and its total debt was $452.17 million. The value of shareholders’ equity is $287.12 million.
Technical Picture
This quick technical analysis looks at Amicus Therapeutics Inc.’s (FOLD) price momentum. With a historical volatility rate of 26.79%, the RSI 9-day stood at 35.32% on 22 September.
With respect to its five-day moving average, the current Amicus Therapeutics Inc. price is down by -6.34% percent or -$0.83. At present, FOLD shares trade -3.31% below its 20-day simple moving average and +3.03% percent above its 100-day simple moving average. However, the stock is currently trading approximately -6.20% below its SMA50 and -0.89% below its SMA200.
Stochastic coefficient K was 14.00% and Stochastic coefficient D was 22.87%, while ATR was 0.42. Given the Stochastic reading of 21.74% for the 14-day period, the RSI (14) reading has been calculated as 39.93%. As of today, the MACD Oscillator reading stands at -0.53, while the 14-day reading stands at -0.51.
Analyst Ratings
Morgan Stanley launched its rating on Amicus Therapeutics Inc. (NASDAQ: FOLD) to an Equal-weight in a note to investors on September 09, 2022. Amicus Therapeutics Inc. (FOLD) has been rated Overweight by analysts. According to 0 brokerage firms, FOLD is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Amicus Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $16.50, the current consensus forecast for the stock is $12.00 – $20.00. Based on these forecasts, analysts predict Amicus Therapeutics Inc. (FOLD) will achieve an average price target of $16.40.
